MRNA-3705 is an oligonucleotide commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MRNA-3705’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MRNA-3705 is expected to reach an annual total of $17 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Moderna is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$19,263 million for the fiscal year ended December 2022 (FY2022), an increase of 4.3% over FY2021. In FY2022, the company’s operating margin was 48.9%, compared to an operating margin of 72% in FY2021. In FY2022, the company recorded a net margin of 43.4%, compared to a net margin of 66.1% in FY2021. The company reported revenues of US$1,862 million for the first quarter ended March 2023, a decrease of 63.4% over the previous quarter.
For a complete picture of MRNA-3705’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.